This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A third look: Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for the potential treatment of obesity and various metabolic disorders
Ticker(s): VKTX, LLYWho's the expert?
- Endocrinologist practicing in New Jersey
- sees around 300 patients in a month as a full time endocrinologist---so I may treat 300-500 or so pts in a year with obesity--- most of these pts have diabetes as this is what I seem mostly in my practice. yes I prescribe mounjaro.
- paid lit review: https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
